Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained ...

AstraZeneca's three-drug inhaler Breztri Aerosphere has shown efficacy for uncontrolled asthma in a pair of phase 3 trials ...

Using advanced imaging technologies as a means to enhance diagnostic accuracy was also of interest. Many HCPs pointed to the ...

"DHE plays a unique clinical role in the acute treatment of migraine, providing patients long-lasting effects and the unique ...

The application has been submitted by the capital investment arm of insurance company Aviva and mixed-use developer Socius, ...

The NIH – which is the world's biggest funder of biomedical research – issued a new policy document yesterday that indicates ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD), setting it on course to become the first non-steroidal ...

MSD is expecting to see an additional $200 million layered onto its costs this year as a result of President Trump's tariffs – even before a possible pharma-specific levy is announced.

In this new series, we will be interviewing five oncologists from a range of different demographics to find out how they prefer to engage with pharma and how this could be improved in the future.

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

Informed consent is a foundational element of every clinical trial. Yet, the traditional paper-based process has long been ...